Nuvectis Pharma, Inc.
NVCT$367M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaFORT LEE13 employees
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
NVCT News
Catalyst Timeline
1 upcoming, 0 past
EarningsNext
NVCT Earnings Report
Aug 4, 2026Confirmed
EPS Est: $-0.25 | FQ end 2026-06
Drug Pipeline
No drugs found in this phase.
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
📑
→Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
Catalyst Verdict
Full breakdown — the signals behind the verdict
Market-Implied Move
Regulatory Approvals
Frequently asked questions
When is Nuvectis Pharma, Inc.'s next FDA catalyst?→
Nuvectis Pharma, Inc.'s (NVCT) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NVCT biotech catalysts?→
Add NVCT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nuvectis Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply